A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Inclusion Criteria: * Recipient age \>= 18 years of age * The recipient is CMV seropositive * The recipient is planned to receive an allogeneic peripheral blood stem cell graft * The recipient is planned to receive fludarabine, melphalan, and total body irradiation for the transplant conditioning regimen * The recipient is planned to receive micro-dose methotrexate, tacrolimus, and mycophenolate mofetil for acute graft versus host disease (GvHD) prophylaxis * The recipient has an expected hematopoietic cell transplantation-comorbidity index (HCT-CI) score of 4 or less based upon the data available at the time of eligibility assessment * The recipient must understand the investigational nature of this study and has signed an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedures * The donor is CMV seronegative or seropositive * The donor is 8/8 human leukocyte antigen (HLA) (DR-B1, A, B, C) matched to the recipient * The donor is willing and able to donate peripheral blood mononuclear cells in addition to peripheral blood stem cells * The donor is willing to sign informed consent Exclusion Criteria: * The recipient is CMV seronegative * The recipient is planned to receive T cell depletion in vivo (anti-thymocyte globulin \[ATG\], alemtuzumab, post-transplant cyclophosphamide) or ex vivo (alpha-beta T cell depleted or CD34+ selected grafts) as acute GvHD prophylaxis * The graft source is …